* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Enorama Pharma AB's PEG Ratio or its related term are showing as below:
OSTO:ERMA's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.685 * Ranked among companies with meaningful PEG Ratio only.
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Enorama Pharma AB (OSTO:ERMA) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Enorama Pharma AB PEG Ratio Related Terms
Enorama Pharma AB PEG Ratio Historical Data
* Premium members only.
The historical data trend for Enorama Pharma AB's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ERMA vs ZTS, UTHR, VTRS: PEG Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Enorama Pharma AB's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enorama Pharma AB PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Enorama Pharma AB's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Enorama Pharma AB's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Enorama Pharma AB (OSTO:ERMA) has a PEG Ratio of 0.00 as of Jul. 11, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Enorama Pharma AB and its competitors. According to the industry distribution chart, Enorama Pharma AB ranks #999999 out of 350 companies in the Drug Manufacturers industry.
Is Enorama Pharma AB's PEG Ratio too high?
Enorama Pharma AB's current PEG Ratio is 0.00. Based on the distribution chart, Enorama Pharma AB ranks #999999 out of 350 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Enorama Pharma AB has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Enorama Pharma AB's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Enorama Pharma AB ranks #999999 out of 350 companies for PEG Ratio. This places Enorama Pharma AB in the lower half of its industry. The industry median PEG Ratio is 1.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.69, based on 350 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Enorama Pharma AB and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enorama Pharma AB's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enorama Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, Enorama Pharma AB (OSTO:ERMA) is currently considered Possible Value Trap. The stock's GF Value™ is kr0.41, compared to a current price of kr0.26 — trading 37.8% below its estimated fair value. The current PEG Ratio is 0.00. Enorama Pharma AB's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Enorama Pharma AB (OSTO:ERMA), the current PEG Ratio is 0.00 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enorama Pharma AB (OSTO:ERMA) Overvalued in 2026?
Based on GuruFocus' analysis, Enorama Pharma AB stock appears to be undervalued.
The current stock price of kr0.26 is trading 37.8% below its estimated GF Value™ of kr0.41.
GuruFocus considers Enorama Pharma AB to be Possible Value Trap.
Key valuation signals for OSTO:ERMA:
PEG Ratio: 0.00
GF Value™: kr0.41 vs. price of kr0.26 (37.8% below fair value)
No single metric tells the full story. See the OSTO:ERMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform.
28GF Score
Get the complete analysis for OSTO:ERMA
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ERMA has been successfully added to your 
